Business Wire

OH-AMERICHEM

5.4.2024 04:34:26 CEST | Business Wire | Press release

Share
Americhem has earned the EcoVadis Silver Medal for Sustainability

Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal. EcoVadis is a globally recognized assessment platform that rates businesses' sustainability in various categories. This result places Americhem amongst the top 15% of companies assessed by EcoVadis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404483358/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Americhem has earned the EcoVadis Silver Medal for Sustainability (Graphic: Business Wire)

The EcoVadis rating also covers a broad range of non-financial management systems including Environmental, Labor and Human Rights, Ethics, and Sustainable Procurement impacts. Americhem’s CEO, John Richard states, “I want to express my deepest gratitude to every employee and partner who has played a role in helping us attain this remarkable achievement. This marks only the beginning for Americhem to set new standards, keep delivering excellence, and pushing boundaries within our sustainability goals.”

Americhem has made major steps forward in sustainability efforts over the past year. Centering a plan around Process, Product, and People has focused Americhem to hone efforts into the areas that matter most and can have the greatest impact. In terms of Process, Americhem’s Denmark plant pioneered a Cold Pounding technology that reduces energy usage by up to 85% and cuts emissions by up to 20% in comparison to conventional compounding processes. The facility is also powered solely by wind and solar energy from RECs Certified suppliers. In the United States, Americhem is recognized as an Operation Clean Sweep® member, with many sites having pledged to achieve zero resin pellet, flake, and powder loss to help keep materials out of the marine environment. In addition, Americhem's plants embrace recycling-compliant packaging, collaborating with customers for the reuse of packaging materials including plastic drums.

On the product front, Americhem has developed numerous technologies that empower customers to attain their sustainability objectives. Solution Dyeing, a technology used in the carpet and textile production processes, eliminates the need for excessive water usage and reduces carbon emissions significantly compared to traditional dyeing processes. Americhem’s flagship additive masterbatch nBalance® allows Post-Consumer Recycled (PCR) materials, which have a yellow tint, to be restored to PET PCR that visually mimics virgin PET.

Americhem recognizes the significance of creating a sustainable environment for both its employees and the communities it serves. The company has also been taking significant steps in its dedication to People Sustainability. By encompassing measures to enhance employee well-being through safety and health initiatives, fostering higher employee engagement through senior management efforts, contributing to charitable causes, and actively participating in volunteer activities, Americhem has noticed an overall increase in employee satisfaction.

Looking ahead, Americhem is committed to making bigger strides in its sustainability journey. In addition to continuous improvement in manufacturing processes, the company plans to further enhance its product portfolio to include sustainability features in most products, develop new product lines for physical and chemical recycling applications, and establish ongoing Life Cycle Assessment (LCA) and Carbon Footprint Analysis on all products.

Americhem would like to thank EcoVadis for their commitment to ensuring that companies remain conscious in their efforts toward a more sustainable future. To learn more about Americhem, please visit: www.americhem.com

About Americhem

Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404483358/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye